Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Ferrous Fumarate→

Ferrous Fumarate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
141-01-5
Molecular formula
C4H2FeO4
Molecular weight
169.9 g/mol
Drug class
Iron replacementferrous (Fe2+) iron source
Mechanism of action
Ferrous iron is absorbed primarily in the duodenum and proximal jejunum through divalent metal transporter 1 (DMT1). Absorbed iron enters the circulating transferrin pool and is incorporated into haemoglobin, myoglobin and iron-dependent enzymes. Fumarate, sulfate, succinate and ascorbate salts deliver the same ferrous iron moiety; elemental iron content and formulation affect dosing and tolerability, not the core deficiency indication.
Indications / reported uses
  • Prevention and treatment of iron deficiency
  • Treatment of iron-deficiency anaemia, including in pregnancy where clinically appropriate; elemental iron dose and tolerability depend on the particular salt and formulation

Sources: NIH Office of Dietary Supplements — Iron fact sheet · NHS — Iron deficiency anaemia · UK product information for ferrous salts

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Ferrous Fumarate Environmental Risk Assessment (ERA) (the Ferrous Fumarate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.